{"id":5471,"date":"2022-03-21T10:07:34","date_gmt":"2022-03-21T14:07:34","guid":{"rendered":"https:\/\/spharm-inc.com\/wp2021\/?p=5471"},"modified":"2025-03-28T16:37:56","modified_gmt":"2025-03-28T20:37:56","slug":"lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire","status":"publish","type":"post","link":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/","title":{"rendered":"L\u2019avis de conformit\u00e9 avec conditions par rapport \u00e0 l\u2019examen prioritaire"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"5471\" class=\"elementor elementor-5471 elementor-3307\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3032b61d elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3032b61d\" data-element_type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[{&quot;jet_parallax_layout_image&quot;:{&quot;url&quot;:&quot;&quot;,&quot;id&quot;:&quot;&quot;,&quot;size&quot;:&quot;&quot;},&quot;_id&quot;:&quot;a36f0df&quot;,&quot;jet_parallax_layout_image_tablet&quot;:{&quot;url&quot;:&quot;&quot;,&quot;id&quot;:&quot;&quot;,&quot;size&quot;:&quot;&quot;},&quot;jet_parallax_layout_image_mobile&quot;:{&quot;url&quot;:&quot;&quot;,&quot;id&quot;:&quot;&quot;,&quot;size&quot;:&quot;&quot;},&quot;jet_parallax_layout_speed&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:50,&quot;sizes&quot;:[]},&quot;jet_parallax_layout_type&quot;:&quot;scroll&quot;,&quot;jet_parallax_layout_direction&quot;:null,&quot;jet_parallax_layout_fx_direction&quot;:null,&quot;jet_parallax_layout_z_index&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_x&quot;:50,&quot;jet_parallax_layout_bg_x_tablet&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_x_mobile&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_y&quot;:50,&quot;jet_parallax_layout_bg_y_tablet&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_y_mobile&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_size&quot;:&quot;auto&quot;,&quot;jet_parallax_layout_bg_size_tablet&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_size_mobile&quot;:&quot;&quot;,&quot;jet_parallax_layout_animation_prop&quot;:&quot;transform&quot;,&quot;jet_parallax_layout_on&quot;:[&quot;desktop&quot;,&quot;tablet&quot;]}]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-63e9c7f3\" data-id=\"63e9c7f3\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3f619b10 elementor-widget elementor-widget-text-editor\" data-id=\"3f619b10\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h1 style=\"text-align: center;\">L\u2019avis de conformit\u00e9 avec conditions par rapport \u00e0 l\u2019examen prioritaire<\/h1><p><span style=\"color: #9b5200;\"><strong>QUELLE EST LA DIFF\u00c9RENCE ENTRE L\u2019AVIS DE CONFORMIT\u00c9 AVEC CONDITIONS ET L\u2019\u00c9VALUATION PRIORITAIRE?<\/strong><\/span><\/p><p>Ces deux processus s\u2019appliquent aux m\u00e9dicaments utilis\u00e9s pour traiter des affections graves, potentiellement mortelles ou pour une maladie s\u00e9v\u00e8rement d\u00e9bilitante (comme la maladie d\u2019Alzheimer, le cancer, le sida ou la maladie de Parkinson).<\/p><p>L\u2019\u00e9valuation prioritaire s\u2019applique aux m\u00e9dicaments qui d\u00e9montrent des preuves substantielles d\u2019efficacit\u00e9 clinique \u00e0 la fin des phases d\u2019essais cliniques, c\u2019est-\u00e0-dire une fois le d\u00e9veloppement clinique termin\u00e9. Le d\u00e9lai total de r\u00e9vision passe de 355 jours \u00e0 215 jours.<\/p><p>D\u2019autre part, l\u2019avis de conformit\u00e9 avec condition (AC-C) s\u2019applique aux m\u00e9dicaments dont l\u2019efficacit\u00e9 clinique est prometteuse tout au long des phases d\u2019essais cliniques. En r\u00e9sum\u00e9, l\u2019AC-C peut \u00eatre accord\u00e9 avec moins de donn\u00e9es cliniques qu\u2019on ne le pr\u00e9voit habituellement, c\u2019est-\u00e0-dire avec les r\u00e9sultats de l\u2019\u00e9tude de phase II ou les rapports provisoires des \u00e9tudes de phase III. Le fabricant est autoris\u00e9 \u00e0 commercialiser et \u00e0 vendre ce m\u00e9dicament \u00e0 la condition que le fabricant effectue des \u00e9tudes suppl\u00e9mentaires pour confirmer les avantages et l\u2019innocuit\u00e9 du m\u00e9dicament. Le d\u00e9lai de r\u00e9vision total passe de 355 jours \u00e0 235 jours.<\/p><p>La condition doit \u00eatre convenue avec Sant\u00e9 Canada. Certaines des conditions de l\u2019AC-C peuvent inclure une exigence de surveiller de pr\u00e8s le m\u00e9dicament concernant son innocuit\u00e9 et ses effets ind\u00e9sirables et de fournir \u00e0 la DGPSA des mises \u00e0 jour r\u00e9guli\u00e8res. Une fois les conditions remplies, la d\u00e9signation \u00abavec condition\u00bb est retir\u00e9e de l\u2019AC.<\/p><p>Afin d\u2019\u00eatre consid\u00e9r\u00e9 pour une \u00e9valuation prioritaire ou un AC-C, le m\u00e9dicament doit r\u00e9pondre aux crit\u00e8res sp\u00e9cifiques de Sant\u00e9 Canada, qui peuvent \u00eatre r\u00e9sum\u00e9s comme suit :<\/p><ul><li>Offrir un traitement, une pr\u00e9vention ou un diagnostic efficace d\u2019une maladie ou d\u2019une condition pour laquelle aucun m\u00e9dicament n\u2019est disponible au Canada; ou<\/li><li>Offrir un meilleur profile avantages \/ risques par rapport aux th\u00e9rapies, aux agents de pr\u00e9vention ou aux agents de diagnostic existants pour une maladie ou une affection, qui n\u2019est pas g\u00e9r\u00e9e ad\u00e9quatement par un m\u00e9dicament d\u00e9j\u00e0 commercialis\u00e9 au Canada.<\/li><\/ul><p>Encore une fois, discuter avec un expert en r\u00e9glementation canadienne au stade pr\u00e9coce de d\u00e9veloppement d\u2019un m\u00e9dicament peut s\u2019av\u00e9rer un avantage d\u00e9terminant permettant d\u2019\u00e9tablir la strat\u00e9gie r\u00e9glementaire id\u00e9ale et de satisfaire les exigences sp\u00e9cifiques au Canada, tout en gardant \u00e0 l\u2019esprit la strat\u00e9gie de mise en march\u00e9 mondiale.<br \/><br \/><\/p><hr \/><h3><br \/>Pour toute question sur le processus canadien d\u2019examen et de r\u00e9glementation des m\u00e9dicaments qui n\u2019est pas couverte dans cette section, n\u2019h\u00e9sitez pas \u00e0 <a style=\"color: #9b5200;\" href=\"https:\/\/spharm-inc.com\/fr\/contactez-nous\/\">communiquer directement avec nous<\/a>.<\/h3><hr \/>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>L\u2019avis de conformit\u00e9 avec conditions par rapport \u00e0 l\u2019examen prioritaire QUELLE EST LA DIFF\u00c9RENCE ENTRE L\u2019AVIS DE CONFORMIT\u00c9 AVEC CONDITIONS ET L\u2019\u00c9VALUATION PRIORITAIRE? Ces deux processus s\u2019appliquent aux m\u00e9dicaments utilis\u00e9s pour traiter des affections graves, potentiellement mortelles ou pour une maladie s\u00e9v\u00e8rement d\u00e9bilitante (comme la maladie d\u2019Alzheimer, le cancer, le sida ou la maladie de [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":6460,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[242],"tags":[],"class_list":["post-5471","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-reglementation-de-sante-canada"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Avis de conformit\u00e9 avec conditions vs examen prioritaire<\/title>\n<meta name=\"description\" content=\"D\u00e9couvrez les diff\u00e9rences entre l&#039;avis de conformit\u00e9 avec conditions et l&#039;examen prioritaire dans l&#039;approbation au Canada.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avis de conformit\u00e9 avec conditions vs examen prioritaire\" \/>\n<meta property=\"og:description\" content=\"D\u00e9couvrez les diff\u00e9rences entre l&#039;avis de conformit\u00e9 avec conditions et l&#039;examen prioritaire dans l&#039;approbation au Canada.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/\" \/>\n<meta property=\"og:site_name\" content=\"Canada&#039;s Drug &amp; Health Product Regulatory Experts\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-21T14:07:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-28T20:37:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1640\" \/>\n\t<meta property=\"og:image:height\" content=\"924\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"SPharm Canada\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@2021-08-24 16:28:44\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"SPharm Canada\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/\",\"url\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/\",\"name\":\"Avis de conformit\u00e9 avec conditions vs examen prioritaire\",\"isPartOf\":{\"@id\":\"https:\/\/spharm-inc.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg\",\"datePublished\":\"2022-03-21T14:07:34+00:00\",\"dateModified\":\"2025-03-28T20:37:56+00:00\",\"author\":{\"@id\":\"https:\/\/spharm-inc.com\/fr\/#\/schema\/person\/a37a21d64482aea4348baedfe3ed845a\"},\"description\":\"D\u00e9couvrez les diff\u00e9rences entre l'avis de conformit\u00e9 avec conditions et l'examen prioritaire dans l'approbation au Canada.\",\"breadcrumb\":{\"@id\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#primaryimage\",\"url\":\"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg\",\"contentUrl\":\"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg\",\"width\":1640,\"height\":924},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/spharm-inc.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L\u2019avis de conformit\u00e9 avec conditions par rapport \u00e0 l\u2019examen prioritaire\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/spharm-inc.com\/fr\/#website\",\"url\":\"https:\/\/spharm-inc.com\/fr\/\",\"name\":\"Canada's Drug & Health Product Regulatory Experts\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/spharm-inc.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/spharm-inc.com\/fr\/#\/schema\/person\/a37a21d64482aea4348baedfe3ed845a\",\"name\":\"SPharm Canada\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/spharm-inc.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6bd2a74a6f9b867851a1cfe6a675fbe0b0734774c6762861ddb4527adaf7e7c3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6bd2a74a6f9b867851a1cfe6a675fbe0b0734774c6762861ddb4527adaf7e7c3?s=96&d=mm&r=g\",\"caption\":\"SPharm Canada\"},\"description\":\"With a quarter of a century of consistent and successful results, SPharm has become one of the leading Drug Regulatory Advisory firms in Canada. Drug companies from around the world count on SPharm to help them navigate the drug (and other health products) review &amp; approval process in Canada. Avec un quart de si\u00e8cle de r\u00e9sultats et de succ\u00e8s constants , SPharm est devenue une entreprise de services de r\u00e9f\u00e9rence au Canada en strat\u00e9gie de d\u00e9veloppement de m\u00e9dicaments et affaires r\u00e9glementaires. Des compagnies pharmaceutiques \u00e0 travers le monde comptent sur SPharm pour faciliter le processus d'homologation de leurs m\u00e9dicaments (et autres produits de sant\u00e9) au Canada.\",\"sameAs\":[\"https:\/\/x.com\/2021-08-24 16:28:44\"],\"url\":\"https:\/\/spharm-inc.com\/fr\/author\/spharm-canada\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avis de conformit\u00e9 avec conditions vs examen prioritaire","description":"D\u00e9couvrez les diff\u00e9rences entre l'avis de conformit\u00e9 avec conditions et l'examen prioritaire dans l'approbation au Canada.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/","og_locale":"fr_FR","og_type":"article","og_title":"Avis de conformit\u00e9 avec conditions vs examen prioritaire","og_description":"D\u00e9couvrez les diff\u00e9rences entre l'avis de conformit\u00e9 avec conditions et l'examen prioritaire dans l'approbation au Canada.","og_url":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/","og_site_name":"Canada&#039;s Drug &amp; Health Product Regulatory Experts","article_published_time":"2022-03-21T14:07:34+00:00","article_modified_time":"2025-03-28T20:37:56+00:00","og_image":[{"width":1640,"height":924,"url":"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg","type":"image\/jpeg"}],"author":"SPharm Canada","twitter_card":"summary_large_image","twitter_creator":"@2021-08-24 16:28:44","twitter_misc":{"\u00c9crit par":"SPharm Canada","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/","url":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/","name":"Avis de conformit\u00e9 avec conditions vs examen prioritaire","isPartOf":{"@id":"https:\/\/spharm-inc.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#primaryimage"},"image":{"@id":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#primaryimage"},"thumbnailUrl":"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg","datePublished":"2022-03-21T14:07:34+00:00","dateModified":"2025-03-28T20:37:56+00:00","author":{"@id":"https:\/\/spharm-inc.com\/fr\/#\/schema\/person\/a37a21d64482aea4348baedfe3ed845a"},"description":"D\u00e9couvrez les diff\u00e9rences entre l'avis de conformit\u00e9 avec conditions et l'examen prioritaire dans l'approbation au Canada.","breadcrumb":{"@id":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#primaryimage","url":"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg","contentUrl":"https:\/\/spharm-inc.com\/wp-content\/uploads\/Lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire.jpg","width":1640,"height":924},{"@type":"BreadcrumbList","@id":"https:\/\/spharm-inc.com\/fr\/lavis-de-conformite-avec-conditions-par-rapport-a-lexamen-prioritaire\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/spharm-inc.com\/fr\/"},{"@type":"ListItem","position":2,"name":"L\u2019avis de conformit\u00e9 avec conditions par rapport \u00e0 l\u2019examen prioritaire"}]},{"@type":"WebSite","@id":"https:\/\/spharm-inc.com\/fr\/#website","url":"https:\/\/spharm-inc.com\/fr\/","name":"Canada's Drug & Health Product Regulatory Experts","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/spharm-inc.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/spharm-inc.com\/fr\/#\/schema\/person\/a37a21d64482aea4348baedfe3ed845a","name":"SPharm Canada","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/spharm-inc.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6bd2a74a6f9b867851a1cfe6a675fbe0b0734774c6762861ddb4527adaf7e7c3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6bd2a74a6f9b867851a1cfe6a675fbe0b0734774c6762861ddb4527adaf7e7c3?s=96&d=mm&r=g","caption":"SPharm Canada"},"description":"With a quarter of a century of consistent and successful results, SPharm has become one of the leading Drug Regulatory Advisory firms in Canada. Drug companies from around the world count on SPharm to help them navigate the drug (and other health products) review &amp; approval process in Canada. Avec un quart de si\u00e8cle de r\u00e9sultats et de succ\u00e8s constants , SPharm est devenue une entreprise de services de r\u00e9f\u00e9rence au Canada en strat\u00e9gie de d\u00e9veloppement de m\u00e9dicaments et affaires r\u00e9glementaires. Des compagnies pharmaceutiques \u00e0 travers le monde comptent sur SPharm pour faciliter le processus d'homologation de leurs m\u00e9dicaments (et autres produits de sant\u00e9) au Canada.","sameAs":["https:\/\/x.com\/2021-08-24 16:28:44"],"url":"https:\/\/spharm-inc.com\/fr\/author\/spharm-canada\/"}]}},"_links":{"self":[{"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/posts\/5471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/comments?post=5471"}],"version-history":[{"count":1,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/posts\/5471\/revisions"}],"predecessor-version":[{"id":27838,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/posts\/5471\/revisions\/27838"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/media\/6460"}],"wp:attachment":[{"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/media?parent=5471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/categories?post=5471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/spharm-inc.com\/fr\/wp-json\/wp\/v2\/tags?post=5471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}